ONCAlert | Upfront Therapy for mRCC

Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian Cancer

Mansoor Mirza, MD
Published Online: 11:50 PM, Mon June 3, 2019


Mansoor Mirza, MD, chief oncologist, Department of Oncology, Copenhagen University Hospital, discusses the findings from NSGO-AVANOVA2/ENGOT-OV24, the randomized controlled chemotherapy-free trial of niraparib (Zejula) and bevacizumab (Avastin) versus niraparib alone in patients with recurrent platinum-sensitive ovarian cancer.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.